List view / Grid view
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
Researchers from the University of Minnesota have developed a 3D spherical microfluidic device. Here, Dr Ruitao Su explains how the new device can be used in drug discovery and development.
Microfluidic screening technologies have been used to discover a promising antibody candidate against SARS-CoV-2 and the South African variant.
Sino Biological has developed 1,000+ cytokines and receptors, including growth factors, cytokines, chemokines, interferons, interleukins, etc.
The global cell-based assays market is expected to grow due to increasing investments into cell-based research and a rise in chronic diseases.
Two screening techniques were used by researchers to find anticancer compounds that target the aryl hydrocarbon receptor.
Solutions to aid understanding of cellular and molecular pathways in diabetes and translate these findings into prevention and treatment strategies.
The development of a Parkinson’s disease model, using hiPSC-derived neural cells, to assess alpha-synuclein pre-formed fibril-induced toxicity.
11 May 2021 | By PerkinElmer
Get the Big Picture and listen to Pharma thought leaders how they view CETSA® and its impact on their Drug Discovery.
A combination of computer simulations and fragment screening have uncovered 27 molecular binding sites on tubulin, a protein of the cell cytoskeleton.
After screening 4,500 compounds using induced pluripotent stem cells, researchers have identified one lead that could treat pulmonary arterial hypertension.
Researchers have shown that Chroman 1, Emricasan and trans-ISRIB, in combination with polyamines, are effective at protecting induced pluripotent stem cells from stress.
Gain more insight into immune-tumor interactions and learn how antibody detection techniques like multiplexing is advancing immunotherapies.
Summary of a neurology publication by Alnylam Pharmaceuticals: large-scale protein screening identifies novel biomarker for onset and progression of lethal ATTRv amyloidosis.
Accelerate your research with an upgradeable platform. Benefit from a fluidic-free assay format for easy and fast kinetics or analyte quantitation.
5,000+ drug target reagents for antibody, small molecule drug discovery and development, including immune checkpoints, cytokines and kinases.
